54.19
price down icon1.45%   -0.80
after-market Handel nachbörslich: 54.19
loading

Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten

pulisher
11:50 AM

Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com

11:50 AM
pulisher
09:13 AM

What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional

09:13 AM
pulisher
Jul 22, 2025

What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025
pulisher
Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025
pulisher
Jul 17, 2025

How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 15, 2025

How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛

Jul 12, 2025
pulisher
Jul 02, 2025

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech

Jul 02, 2025
pulisher
Jul 01, 2025

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com

Jul 01, 2025
pulisher
Jun 30, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman

Jun 30, 2025
pulisher
Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus

Jun 26, 2025
pulisher
Jun 24, 2025

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance

Jun 24, 2025
pulisher
Jun 20, 2025

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Insider Monkey

Jun 20, 2025
pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citi initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 16, 2025

How To Trade (PTGX) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 16, 2025
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):